Lendormin D® Tablet (Drug Use Result Survey)

Study to investigate the safety and the efficacy in patients with insomnia, receiving Lendormin D tablet under condition of normal clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sleep Initiation and Maintenance Disorders Dyssomnias Mental Disorders Nervous System Diseases Sleep Disorders, Intrinsic Sleep Wake Disorders

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with insomnia

Exclusion criteria

none

Treatment and study plan

Lendormin D tablets

Drug

Primary outcomes

Number of patients with adverse events

Time frame: up to 2 months
Number of patients with adverse drug reactions

Time frame: up to 2 months
Number of patients with serious adverse events

Time frame: up to 2 months

Secondary outcomes

Physician's overall efficacy assessment on a 3-point scale

Time frame: up to 2 months
Patient's impression questionnaire

Time frame: up to 2 months

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Important dates

Study start: 2005
Primary completion: 2006
First posted: Aug 22, 2014
Registry last updated: Aug 22, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed